ABSTRACT. The effects of various selective phosphodiesterase (PDE) inhibitors on muscle contractility and cyclic nucleotide contents in the guinea pig gall bladder were investigated. Various selective PDE inhibitors, vinpocetine (type 1), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, type 2), milrinone (type 3), Ro20-1724 (type 4), and zaprinast (type 5), inhibited CCh-induced contractions in a concentration-dependent manner. The rank order of potency for the gall bladder was Ro20-1724 > vinpocetine > EHNA >milrinone > zaprinast, which was different from that of the trachea, taenia coli, and aorta. In the presence of CCh (0.3 µM), vinpocetine, milrinone, and Ro20-1724 each increased cAMP content, but not cGMP. By contrast, zaprinast increased cGMP content, but not cAMP, and EHNA increased both cAMP and cGMP contents. These results suggest that vinpocetine-, milrinone-, and Ro20-1724-induced relaxation was correlated with cAMP, zaprinast-induced relaxation was correlated with cGMP, and that EHNA-induced relaxation was correlated with cAMP and cGMP in the guinea pig gall bladder. In conclusion, the effect of PDE inhibitors in the guinea pig gall bladder was different from those in smooth muscles, such as the trachea, taenia coli, and aorta. KEY WORDS: cAMP, cGMP, Gall bladder, PDE inhibitor.
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are important second messengers, and have been associated with smooth muscle relaxation [5] . These cyclic nucleotides are synthesized by adenylyl cyclase or guanylyl cyclase, and are degraded by phosphodiesterase (PDE). Currently, PDEs are classified into 11 families [3, 6, 23] , and selective PDE inhibitors have been found [4] . It has been reported that the relaxation induced by these selective PDE (type 1-type 5) inhibitors is involved in the increases in cAMP and/or cGMP contents in vascular [14] , tracheal [16] , urinary [15, 22] , and intestinal smooth muscle [10, 11] . Since PDE1 and 2 hydrolyze cAMP and/or cGMP [3] , it is thought that type 1 and type 2 inhibitor-induced relaxations may be correlated with increases in cAMP and/or cGMP in smooth muscles. It has been reported that vinpocetine (type 1 inhibitor) induced relaxation in the rabbit aorta through the increase in cGMP content [1, 7] , and in the rat urinary bladder [15] and guinea pig taenia coli [10] through an increase in the cAMP content. There have been few reports indicating that relaxation induced by EHNA (type 2 inhibitor) is associated with the increases in the cyclic nucleotide contents of smooth muscle [9, 11, 13] .
Additionally, the relationship of relaxation induced by these selective inhibitors and cyclic nucleotides is less clear in the smooth muscle of the gastrointestinal tract. Barnette et al. [2] assessed the activity of PDE families and the relaxation induced by the PDE3, 4, and 5 inhibitors in canine colonic smooth muscle. They showed that PDE3 and 4 inhibitors decreased the hydrolysis of cAMP, that the PDE5 inhibitor decreased the hydrolysis of cGMP, and that the type 4 inhibitor was more potent than the other inhibitors.
Recently, we showed that the rank order of inhibitory potency on carbachol-induced contraction in the smooth muscle of guinea pig taenia coli was type 5 > type 1 > type 2 > type 4 > type 3, and that type 1 and type 4-induced relaxation was correlated with cAMP, although type 2 and type 5-induced relaxation was correlated with cGMP [11] . These reports probably indicate that the differences in inhibitory effects of these selective PDE inhibitors on muscle contractility are due to the distribution of the PDE families in the smooth muscles of the gastrointestinal tract.
In the present study, we have used selective PDE (type 1-5) inhibitors to examine the effects of contractility of the smooth muscles in the guinea pig gall bladder, part of the gastrointestinal tract, and to compare with those of the trachea, teania coli, and aorta. In addition, we also investigated the relationship between relaxation and cyclic nucleotide contents in carbachol-induced contractions of the gall bladder by type 1-5 inhibitors.
MATERIALS AND METHODS

Muscle preparations and tension measurement:
Male guinea pigs (Hartley strain, 300-400 g; Funabashi Farm, Funabashi ) were bled after being stunned, and then the trachea, thoracic aorta, taenia coli and gall bladder were quickly removed. The aorta was cut into spiral strips and the other muscles were made in longitudinal strips. The endothelium and epithelium were removed by gentle rubbing the inner surface of the aorta and trachea with absorbent cotton. The muscle strips were incubated with physiological salt solution (PSS) containing (in mM) 136.8 NaCl, 5.4 KCl, 2.5 CaCl 2 , 1.0 MgCl 2 , 11.9 NaHCO 3 , and 5.5 glucose. PSS was aerated with 95% O 2 and 5% CO 2 to adjust pH to 7.2 at 37°C. This study was conducted in accordance with the Guideline for the Care and Use of Laboratory Animals of Nippon Veterinary and Animal Science University.
Muscle tension was recorded isometrically. One end of each strip was bound to a glass holder and the other end was connected by a silk thread to a strain-gauge transducer (TB-611T; Nihon Kohden, Tokyo) in an organ bath containing PSS with a resting tension of 1 g. The muscle strips were equilibrated for 30 min to obtain a stable contractility induced by hyperosmotically added 65 mM KCl. When the contractile response induced by 0.3 µM carbachol (CCh) or 10 µM phenylephrine (PE) reached a steady level about 15-20 min after addition to a trachea, aorta, teania coli, and gall bladder, vinpocetine (type 1), EHNA (type 2), milrinone (type 3), Ro20-1724 (type 4), or zaprinast (type 5) was added cumulatively.
Assay of cGMP or cAMP content: The cGMP and cAMP content in the muscle strips was measured by enzyme immunoassay, as reported previously [11] . After incubation of the strips with each of the PDE inhibitors for 10 min in the presence of carbachol (0.3 µM), the strips were rapidly frozen in liquid nitrogen, and stored at -80°C until homogenized in 6% trichloroacetic acid (0.4 ml). The homogenate was centrifuged at 3000 × g for 15 min, and the supernatant was washed with 1.5 ml of water-saturated diethyl ether four times. The cGMP and cAMP content of the strips was assayed with an enzyme immunoassay kit (Amersham Pharmacia Biotech, UK). The cGMP and cAMP content was expressed as picomole per gram wet weight.
Chemicals: The chemicals used were milrinone, zaprinast, carbachol (Sigma, St. Louis, MO, U.S.A.), vinpocetine, erythro-9-(2-hydroxy-3-nonyl) adenine•HCl (EHNA) (BIOMOL Research Laboratories, U.S.A.), and Ro20-1724 (LC Laboratories New Boston U.S.A.). Vinpocetine crystallizes if the concentration of vinpocetine exceeds 30 µM in PSS. Therefore, we used vinpocetine below 30 µM in the present experiment.
Statistics: Values are expressed as mean ± SEM, and the IC 50 values (the concentration producing 50% relaxation) were determined by linear regression analysis. Statistical analyses were performed by Student's t-test.
RESULTS
Effects of various selective PDE inhibitors on contractility:
Vinpocetine, EHNA, milrinone, Ro20-1724, and zaprinast inhibited CCh-induced contractions in a concentrationdependent manner in the gall bladder, trachea, and taenia coli (Figs. 1A, and B, C and 2A, B, and C). Furthermore, these agents inhibited PE-induced contractions in a concentration-dependent manner in the aorta (Figs. 1 D and 2D). The concentrations of these agents producing 50% relaxation (IC 50 ) and the maximum relaxation of CCh-or PEinduced contractions are presented in Table 1 . IC 50 and the maximum inhibition of vinpocetine in the gall bladder were similar to those in the other muscles. IC 50 and the maximum inhibition of EHNA and Ro20-1724 in the gall bladder were more potent than those in other muscles. In the gall bladder, IC 50 and the maximum inhibition of milrinone were less potent than those in the trachea and aorta, and IC 50 and the maximum inhibition of zaprinast were much less potent than those in the taenia coli.
The rank orders for the relaxant effect were Ro20-1724 > vinpocetine > EHNA >milrinone > zaprinast for the gall bladder, Ro20-1724 > milrinone > vinpocetine > zaprinast > EHNA for the trachea, zaprinast > vinpocetine > EHNA > Ro20-1724 > milrinone for the taenia coli, and milrinone > vinpocetine > Ro20-1724 > zaprinast > EHNA for the aorta.
Effects of various PDE inhibitors on cGMP and cAMP contents in the gall bladder: Vinpocetine, milrinone, and Ro20-1724 caused concentration-dependent increases in the cAMP content of the gall bladder (Figs. 3A, C, and D), and higher concentrations (100 µM) were required to cause a significant increase in cAMP content for EHNA (Fig. 3B ). There was a positive correlation between the relaxation of the CCh-induced contractions and the increase in cAMP content elicited by vinpocetine, EHNA, milrinone, and Ro20-1724. However, at a concentration that induced halfmaximum relaxation, the Ro20-1724-increased cAMP content was smaller than those of the other inhibitors (Fig. 4A) .
On the other hand, EHNA caused concentration-dependent increases in cGMP content of the gall bladder in the presence of CCh, and higher concentrations (100 µM) were required to cause a significant increase in cGMP content (Fig. 3B) . Zaprinast also caused a concentration-dependent increase in cGMP content (Fig. 3E ), but vinpocetine, milrinone, and Ro20-1724 did not significantly increase the cGMP content above control (Figs. 3A, C, and D) . There was a positive correlation between the relaxation and the increase in cGMP content elicited by EHNA and zaprinast. However, at a concentration that induced half-maximum relaxation, EHNA-increaesd cGMP content was less than that of zaprinast (Fig. 4B) .
DISCUSSION
The functional role of PDE families has been examined in several smooth muscle preparations as follows. It has been shown that PDE type 3 and type 4 inhibitors had more potent effects than the other PDE inhibitors on the pre-contracted trachea [16] , and that type 3 inhibitors had the most potent effects on the aorta [14] . In the guinea pig trachea, milrinone, a PDE type 3 inhibitor, and Ro20-1724, a PDE type 4 inhibitor, inhibited CCh-induced contractions, and their IC 50 values were 30 µM [8] . Moreover, in the rat aorta, milrinone and Ro20-1724 inhibited norepinephrineinduced contractions and their IC 50 values were 6 µM and 240 µM, respectively [18] . Our present results were consistent with these reports. IC 50 of milrinone and Ro20-1724 in the trachea were similar, but IC 50 of milrinone was larger than that of Ro20-1724 in the aorta. In the present study, selective PDE inhibitors inhibited CCh-induced contractions in the trachea, gall bladder, and taenia coli, and the rank order of inhibitory potency was Ro20-1724 > milrinone > vinpocetine > zaprinast > EHNA for the trachea, Ro20-1724 > vinpocetine > EHNA >milrinone > zaprinast for the gall bladder, and zaprinast > vinpocetine > EHNA > Ro20-1724 > milrinone for the taenia coli. For the aorta, selective PDE inhibitors inhibited PE-induced contractions, and the rank order of inhibitory potency was milrinone > vinpocetine > Ro20-1724 > zaprinast > EHNA. Furthermore, IC 50 of Ro20-1724 in the gall bladder was the lowest in this experiment. There were a few reports that showed the effects of selective PDE inhibitors on muscle contractility in the smooth muscle of the gastrointestinal tract. Barnette et al. [2] showed that PDE type 4 inhibitors were more potent than PDE type 3 and type 5 inhibitors in canine colonic smooth muscle. Tomkinson and Raeburn [21] investigated the inhibitory potency of PDE type 1, 3, 4, and 5 inhibitors on methacholine-induced contractions in the guinea pig and rat ileal smooth muscle, and showed that type 5 inhibitors were more potent than the other inhibitors. These reports and our data showed that the inhibitory effect of type 5 inhibitors in the gall bladder was similar to that in the colon. We also showed that the effect of the inhibitors in the taenia coli was similar to that in the ileum [10, 11] . These results suggest that the differences in inhibitory potency on PDE inhibitors in the gastrointestinal tract is due to the distribution of PDE families.
It has been reported that vinpocetine (type 1 inhibitor) induces relaxation by increasing the cGMP content in the rabbit aorta [1, 7] . However, in the rat urinary bladder [15] and the guinea pig taenia coli [11] , vinpocetine induces relaxation through an increase in the cAMP content. In the present study, there was a positive correlation between the inhibition of CCh-induced contractions and the increase in cAMP content by vinpocetine in the guinea pig gall bladder. These results suggested that the relaxation induced by PDE type 1 inhibitor was involved in the increase in cAMP content in the guinea pig gall bladder. PDE1 families are identified as PDE1A, 1B, and 1C. PDE1A and 1B have high affinity for cGMP, and PDE1C has a similar affinity for cAMP and cGMP [3] . It is known that PDE1 hydrolyzes cGMP in some smooth muscle cells [17] . However, vinpocetine might inhibit PDE1C, but not PDE1A and B in the guinea pig gall bladder. It has been suggested that EHNA (type 2 inhibitor) relaxes the rat pulmonary artery tone by increasing the cAMP and cGMP content [9] . Additionally, it has been reported that the relaxation induced by EHNA might be involved in the increase in cAMP content in the urinary bladder [15] and taenia coli [11] . In this paper, we showed that there was a positive correlation between the inhibition of CCh-induced contractions and the increase in cAMP or cGMP content caused by EHNA. However, EHNA-evoked increases of cGMP content at a concentration that induced a medium-sized relaxation, was lower than that of zaprinast.
This difference in potency of cGMP in these inhibitors is due to the fact that EHNA increased both the cAMP and cGMP contents, while zaprinast only increased the cGMP content in the gall bladder. These results suggested that the relaxation induced by PDE type 2 inhibitor was involved in the increase in the cAMP and cGMP contents in the guinea pig gall bladder. The present data showed that the relationship between type 2 inhibitor-induced relaxation and the increase in cyclic nucleotides in the guinea pig gall bladder was different from that in the guinea pig taenia coli [11] .
In the guinea pig taenia coli, the inhibition of CChinduced contractions by milrinone (type 3 inhibitor) was less than that of the other PDE inhibitors, and milrinone did not significantly increase the cAMP and cGMP content [11] . In the present study, there was a positive correlation between the inhibition of CCh-induced contractions and the increase in the cAMP content by milrinone in the guinea pig gall bladder. These results suggested that the difference in the inhibitory effect on PDE3 inhibitors is due to the distribution of PDE3 families in the gastrointestinal tract. It is well known that PDE4 is specific for the hydrolysis of cAMP [3] . It has been reported that rolipram (type 4 inhibitor) relaxed bovine trachea by an increase in the cAMP content [19] . In the present study, there was a positive correlation between the inhibition of CCh-induced contractions and the increase in cAMP content elicited by Ro20-1724 in the gall bladder. These data suggest that Ro20-1724 (type 4 inhibitor) induces the relaxation by an increase cAMP content in some kinds of smooth muscle. However, at a concentration that induced half-maximum relaxation, Ro20-1724-increased cAMP content was less than that of the other inhibitors. We reported that MBCQ, a selective PDE 5 inhibitor, inhibits muscle contraction without changes in cAMP and cGMP content in ileal smooth muscle [12] . Therefore, it seems that Ro20-1724-induced relaxation may be partially involved in the cAMP-and cGMP-independent mechanism. Further study is needed to clarify the mechanisms of the cAMP-and cGMP-independent mechanism on Ro20-1724-induced relaxation in the guinea pig gall bladder.
In the present study, there was a positive correlation between the inhibition of CCh-induced contractions and the increase in cGMP content elicited by zaprinast in the gall bladder. These data were consistent with the report that type 5 inhibitor relaxed the rat aorta by an increase in the cGMP content [20] .
In conclusion, selective PDE inhibitors inhibited CChinduced contractions in the guinea pig gall bladder, and the rank order of inhibitory potency was Ro20-1724 (type 4) > vinpocetine (type 1) > EHNA (type 2) > milrinone (type 3) > zaprinast (type 5). The gall bladder and taenia coli belong to the gastrointestinal tract, but the rank order of these PDE inhibitors in the gall bladder was different from that of taenia coli. Moreover, it was indicated that vinpocetine-, EHNA-, milrinone-, and Ro20-1724-induced relaxation has a correlation with cAMP, and that EHNA-and zaprinastinduced relaxation has a correlation with cGMP in the gall bladder. 
